{"id":"etavopivat-c","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Elevated uric acid levels"}]},"_chembl":{"chemblId":"CHEMBL4650332","moleculeType":"Small molecule","molecularWeight":"457.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etavopivat is a pyruvate dehydrogenase kinase inhibitor that increases pyruvate dehydrogenase activity, leading to increased acetyl-CoA production and reduced reactive oxygen species in red blood cells. This metabolic shift decreases hemolysis and improves red blood cell survival in patients with sickle cell disease, reducing vaso-occlusive crises and hemolytic anemia.","oneSentence":"Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:25.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease (to reduce hemolysis and vaso-occlusive crises)"}]},"trialDetails":[{"nctId":"NCT06609226","phase":"PHASE3","title":"A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-10","conditions":"Sickle Cell Disease, Thalassemia","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Etavopivat C","genericName":"Etavopivat C","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etavopivat C is being studied as a potential treatment for Sickle Cell Disease and Thalassemia in a clinical trial. The trial, NCT06609226, is sponsored by Novo Nordisk A/S and is investigating the long-term effects of Etavopivat C in people with these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}